Medicenna Therapeutics Corp. (MDNAF)
| Previous Close | 1.3400 |
| Open | 1.3328 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.2700 - 1.3686 |
| 52 Week Range | 0.1510 - 1.5600 |
| Volume | |
| Avg. Volume | 118,974 |
| Market Cap | 88.44M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jun 25, 2024 - Jul 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.48 |
- Baystreet
Stocks in play: Medicenna Therapeutics Corp.
Presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions ...
GlobeNewswireMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients Durable stable disease (SD) in 3 melanoma patients for 6 to 18 months with concomitant tumor shrinkage With response rate and clinical benefit rate increasing to 29% and 50% (4 PR, 3 SD), respectively, MDNA11 continues to demonstrate compelling single-agent activity in the ABILITY-1 stud
- GlobeNewswire
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicity MDNA113 is our most advanced pre-clinical candidate that targets IL-13Rα2, a tumor associated antigen, which is overexpressed by immunologically “cold” tumors with high unmet needs in pancreatic, prostate, ovarian, breast
